So we’ll wait to see. I think the important outcomes that will be looked at will, of course, be radiographic screen progression and then OS. OS data will also trail a little bit because by definition, we have to let that data mature a bit. But I can assure you, there will be lots of discussions about these data, and there’ll be many players in the marketplace who will want to understand how the data are different and what they say. I will say, in general, though, and this is something you’ve heard us say before that from a radiopharmaceutical perspective, One of the things that we see as an absolute constant in this market is the willingness to embrace additional products just because of the supply chains associated with these projects and like and products and like, there is more so than I’d say in other non-radiopharmaceutical categories a willingness for physicians and the desire of physicians have access to more than one type of product.
And we think that will be very positive for PNT2002 and PNT2003.
Operator: Thank you. One more for your next question. We have a follow-up question from Roanna Ruiz of Leerink Partners. Roanna, your line is open.
Roanna Ruiz : Great. Thanks for taking the follow-up. So I wanted to check in about your contracts with the large PMF networks for a second. Like how long do some of these last? And can you remind us, are you planning to add new ones in the near term or revamp some contracts? And could they help guarantee some exclusivity in terms of holding majority preferred morning time manufacturing positions for PYLARIFY and things like that?
Paul Blanchfield: Thanks, Roanna. I appreciate the question. So as we’ve shared in the past, we have a multichannel PMF strategy across the US. We’re currently working with 47 PMFs, up almost 75% year-over-year and are able to offer PYLARIFY, it’s a little over 95% of the US population just based on drive times and where we do those. A number of our PMF contracts, we’ve shared publicly go out a number of years, including the 2027 and beyond. We are not exclusive to any individual PMF chain, although some of our partners are exclusive to us. We have been working for this for a number of years to ensure that PYLARIFY is remaining accessible, including in those predetermined manufacturing time slots that we’ve continued to work through and optimize as medical practice has become more clear.
And so we feel very comfortable in our PMF position to be able to continue to provide the market-leading product at the times and days in which our customers require it. We do naturally continue to work with our PMF partners to expand redundancy to create more supply. And we really think that’s a unique value proposition that is not replicated by any other PSMA imaging agent, including recently approved F-18 competitors.
Operator: All right. So ladies and gentlemen, there are no further questions at this time. Thank you for participating in today’s conference. This concludes the program. You may now disconnect, and have a wonderful day.
